Syenza’s News Roundup: Launching a New Era of Healthcare Insights

By Staff Writer

September 7, 2023

We are excited to announce the launch of our new newsletter, “Value Science Weekly”. This weekly digest is designed to keep you up-to-date on the latest trends, insights, and breakthroughs in Health Economics and Outcomes Research (HEOR), Global Market Access, and Dynamic Intelligence.

In our next week’s issue, we delve into the transformative potential of virtual care in neurology, as highlighted by the World Health Organization. The rising demand for continuous home and institutional care, driven by an ageing population and increasing prevalence of chronic diseases, is being met head-on by advancements in virtual care. Our rapid insight article explores how virtual care is reshaping patient evaluation, treatment, and follow-up, particularly in the field of neurology.

But that’s just the beginning. Each week, our newsletter will bring you expert perspectives and thought-provoking analyses from renowned researchers and industry leaders. You’ll also discover the latest studies and real-world evidence shaping the economic value and patient outcomes of healthcare interventions. Plus, we’ll keep you informed about policy changes, regulatory updates, and reimbursement frameworks that could impact your work.

We’re also excited to share innovations in market access and healthcare delivery, showcasing the cutting-edge technologies and transformative approaches that are emerging in our industry.

Don’t miss out on these valuable insights. Subscribe to “Value Science Weekly” today for your weekly dose of healthcare innovation news. We look forward to embarking on this journey with you.

Reference url

Recent Posts

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

Tolebrutinib MS analysis
          

Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS

💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?

A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.

Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.

#SyenzaNews #HealthEconomics #MarketAccess

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.